NuCana (NASDAQ:NCNA) is a biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its proprietary ProTide technology to transform some of the most widely used chemotherapy agents into more effective and safer medicines. While primarily listed on the NASDAQ stock exchange, this innovative firm is dedicated to advancing a broad and deep pipeline, centered around transformative oncology drug candidates. Their projects aim to tackle various cancer types, with an ongoing commitment to both research and development in striving to meet unmet medical needs within the oncology space. NuCana's objectives are clearly defined around pushing the boundaries of what current treatments can achieve, aiming to offer new hope and possibilities for patients facing cancer.